News

Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Eli Lilly Files Slew of Lawsuits Over Zepbound and Mounjaro
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Fierce Pharma4d
Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...
Zacks.com on MSN2h
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...
BioSpace5d
Lilly Takes Four Compounders to Court for Allegedly Producing Knockoff Tirzepatide
In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...
Devdiscourse5d
Eli Lilly Intensifies Legal Battle Over Tirzepatide Knockoff Sales
Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...
Pharmaceutical Technology on MSN4d
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...